Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Income from Non-Controlling Interests (2016 - 2018)

Historic Income from Non-Controlling Interests for Pharma (IGC) over the last 10 years, with Q1 2018 value amounting to $634.0.

  • Pharma's Income from Non-Controlling Interests rose 10509.28% to $634.0 in Q1 2018 from the same period last year, while for Jun 2018 it was $320.0, marking a year-over-year decrease of 9841.95%. This contributed to the annual value of $14399.0 for FY2017, which is 15602.29% up from last year.
  • Latest data reveals that Pharma reported Income from Non-Controlling Interests of $634.0 as of Q1 2018, which was up 10509.28% from -$230.0 recorded in Q4 2017.
  • Over the past 5 years, Pharma's Income from Non-Controlling Interests peaked at $38088.0 during Q4 2016, and registered a low of -$42000.0 during Q4 2015.
  • Over the past 5 years, Pharma's median Income from Non-Controlling Interests value was -$5073.0 (recorded in 2016), while the average stood at -$3364.4.
  • As far as peak fluctuations go, Pharma's Income from Non-Controlling Interests plummeted by 1582044.2% in 2014, and later soared by 45088.67% in 2015.
  • Over the past 5 years, Pharma's Income from Non-Controlling Interests (Quarter) stood at -$8882.0 in 2014, then plummeted by 372.87% to -$42000.0 in 2015, then surged by 190.69% to $38088.0 in 2016, then tumbled by 100.6% to -$230.0 in 2017, then surged by 375.65% to $634.0 in 2018.
  • Its last three reported values are $634.0 in Q1 2018, -$230.0 for Q4 2017, and -$84.0 during Q3 2017.